Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents (Q37929159)

25 August 2017

1 reference

title

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents (English)

1 reference

25 August 2017

0 references

Baptist Gallwitz

1

1 reference

25 August 2017

1 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

71

1 reference

25 August 2017

1675-1688

1 reference

25 August 2017

13

1 reference

https://scigraph.springernature.com/pub.10.2165/11592810-000000000-00000

25 August 2017

0 references

cites work

Update on nonautoimmune diabetes in children

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Islet beta cell failure in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

The incretin concept today

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Exenatide: a new option for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

The evolving place of incretin-based therapies in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Incretin-based therapies: viewpoints on the way to consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Potential of liraglutide in the treatment of patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Liraglutide: a new treatment for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Biodegradable poly(DL-lactide-co-glycolide) microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Gastric distention activates satiety circuitry in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

New potential adjuncts to treatment of children with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592810-000000000-00000

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

12 December 2020

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

12 December 2020

Incretin hormones and their therapeutic potential in patients with type 2 diabetes. Preface

1 reference

12 December 2020

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

1 reference

12 December 2020

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

1 reference

12 December 2020

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

1 reference

12 December 2020

The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

1 reference

12 December 2020

Exenatide and rare adverse events

1 reference

12 December 2020

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

1 reference

12 December 2020

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

12 December 2020

Exenatide and rare adverse events

1 reference

12 December 2020

An overview of incretin clinical trials

1 reference

12 December 2020

Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass

1 reference

12 December 2020

Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4

1 reference

12 December 2020

10.2165/11592810-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

21902291

Dimensions Publication ID

25 August 2017

0 references

1 reference

PubMed ID

21902291